Fused polycyclic 2-aminopyrimidine derivatives
US6133257A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 18, 1998 |
| Grant date | Oct 17, 2000 |
| Priority date | — |
| Expiry date | Jun 18, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Fused polycyclic 2-aminopyrimidines of formula (1) are described: wherein PA0 R.sup.1 is a group --L.sup.1 R.sup.2 where L.sup.1 is a covalent bond or a linker atom or group and R.sup.2 is a group --(Alk).sub.m L.sup.2 R.sup.3 where Alk is an optionally substituted aliphatic or heteroaliphatic chain, m is zero or the integer 1, L.sup.2 is a covalent bond or a linker atom or group and R.sup.3 is an optionally substituted cycloaliphatic or heterocycloaliphatic group provided that when m is zero PA0 L.sup.2 is a covalent bond; PA0 Ar is an aryl or heteroaryl group; PA0 X is a carbon or nitrogen atom; PA0 Y is a carbon or nitrogen atom; PA0 Z is a linker group; PA0 A together with X and Y forms an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group; PA0 and the salts, solvates, hydrates and N-oxides thereof. The compounds are potent and selective inhibitors of protein kinases, especially src-family protein kinases and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.